Ranolazine

Ranolazine
Clinical data
Trade names	Ranexa, Aspruzyo Sprinkle, Corzyna
AHFS/Drugs.com	Monograph
MedlinePlus	a606015
License data	US DailyMed: Ranolazine;
Routes of; administration	By mouth
ATC code	C01EB18 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	35 to 50%
Protein binding	~62%
Metabolism	Extensive in liver (CYP3A, CYP2D6) and intestine
Elimination half-life	1.4 to 1.9 hours
Excretion	Kidney (75%) and fecal (25%)
Identifiers
	IUPAC name (RS)-N-(2,6-Dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl]piperazin-1-yl]acetamide;
CAS Number	95635-55-5 ;
PubChem CID	56959;
IUPHAR/BPS	7291;
DrugBank	DB00243 ;
ChemSpider	51354 ;
UNII	A6IEZ5M406;
ChEBI	CHEBI:87681 ;
ChEMBL	ChEMBL1404 ;
CompTox Dashboard (EPA)	DTXSID3045196 ;
ECHA InfoCard	100.149.259
Chemical and physical data
Formula	C24H33N3O4
Molar mass	427.545 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES O=C(Nc1c(cccc1C)C)CN3CCN(CC(O)COc2ccccc2OC)CC3;
	InChI InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29) ; Key:XKLMZUWKNUAPSZ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Ranolazine, sold under the brand name Ranexa among others, is a medication used to treat heart related chest pain. Typically it is used together with other medications when those are insufficient. Therapeutic benefits appear smaller in females than males. It is taken by mouth.

Common side effects include constipation, headache, nausea, and dizziness. Serious side effects may include QT prolongation. Ranolazine is contraindicated (not recommended) in those with liver cirrhosis. How it works is not clear but may involve adenosine triphosphate.

Ranolazine was approved for medical use in the United States in 2006. In 2022, it was the 232nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.